Combination of Veliparib + Lapatinib
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Triple Negative Breast Cancer
Conditions
Metastatic Triple Negative Breast Cancer
Trial Timeline
Sep 4, 2014 → Jul 22, 2021
NCT ID
NCT02158507About Combination of Veliparib + Lapatinib
Combination of Veliparib + Lapatinib is a pre-clinical stage product being developed by AbbVie for Metastatic Triple Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02158507. Target conditions include Metastatic Triple Negative Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Triple Negative Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02158507 | Pre-clinical | Completed |
Competing Products
20 competing products in Metastatic Triple Negative Breast Cancer